Aardvark Therapeutics, Inc. Common Stock (AARD) Stock Score, Valuation & Financial Research

Aardvark Therapeutics, Inc. Common Stock is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for AARD

Aardvark Therapeutics, Inc. Common Stock does not currently have a complete Wall Street Score. The stored market price is USD 5.27. These figures are a research snapshot, not a buy or sell recommendation.

What Aardvark Therapeutics, Inc. Common Stock does

Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Aardvark Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research and development of novel, small-molecule therapeutics designed to activate innate homeostatic pathways for the treatment of metabolic diseases, with the goal of eventually commercializing these drug candidates.

Products and services

  • The company's primary product candidate is ARD-101, a small-molecule therapeutic currently in clinical development for the treatment of metabolic diseases, including hypothalamic obesity.

Customer types

Healthcare providers and patients.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party CROs and CMOs for clinical trial management, data collection, and the manufacturing of drug supplies for clinical studies. Specific supplier names are not disclosed. Source

Business strengths to evaluate

  • Proprietary small-molecule therapeutic platform targeting innate homeostatic pathways Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on the success of a single lead product candidate, ARD-101 Source
  • Risks associated with clinical trial outcomes and regulatory approval processes Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

AARD financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 5.27
Market capitalization:
115.33M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -69.89M
Free cash flow:
USD -54.27M
Cash:
USD 73.85M
Total debt:
USD 677K
EPS:
USD -3.21

What stands out

  • Free cash flow is USD -54.27M, negative for the stored period.
  • The balance sheet shows USD 73.85M of cash versus USD 677K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a limited financial history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 73.17M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for AARD

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can AARD fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is AARD likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for AARD to reach sustainable profitability?
  • What does the current limited financial history warning mean for the reliability or interpretation of AARD's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research AARD

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.